Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07108283) titled 'A Study of Zasocitinib in Adults With Nonsegmental Vitiligo' on Aug. 5.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Investigator, Outcomes Assessor).
Primary Sponsor: Takeda
Condition:
Nonsegmental Vitiligo
Intervention:
Drug: Zasocitinib
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: November 14, 2025
Target Sample Size: 200
Countries of Recruitment:
United States
Canada
China
France
Italy
Japan
Mexico
Poland
Spain
Canada
China
France
Italy
Japan
Mexico
P...